Ezallor Sprinkle

(Rosuvastatin 20)

ApprovedSmall molecule

AstraZeneca

Ezallor Sprinkle is one of 125 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

124

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Vascular DiseaseActive, not recruiting

Left Ventricular Diastolic DysfunctionActive, not recruiting

FunctionRecruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Vascular DiseasePreclinical

Active, not recruiting

Left Ventricular Diastolic DysfunctionApproved

Active, not recruiting

FunctionPhase 2

Recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Geodon

Primacor

Cardene

Sun Pharmaceutical Industries, Inc.

Midamor

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—6

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—7

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ezallor Sprinkle

1 9

Colcrys

Jazz Pharmaceuticals

Phase 3

1 10

Pelacarsen

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Function

NCT07460960

Q2 2029

N/ARecruiting

Vascular Disease

NCT06231966

Clinical

Trials by Indication[1]

Function1 trial

TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men

Recruiting·LLomonosov Moscow State University Medical Research and Educational Center·Phase 2·NCT07460960·150 enrolled

Cardiovascular Disease1 trial

RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)

Unknown status·YYonsei University·N/A·NCT03044665·3,780 enrolled

Vascular Disease1 trial

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

Recruiting·YYonsei University·N/A·NCT06231966·2,462 enrolled

Left ventricular diastolic dysfunction1 trial

Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

Unknown status·YYonsei University·Phase 4·NCT04433533·200 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 12, 2003

CRESTOR

NDA NDA021366

Dec 18, 2018

EZALLOR SPRINKLE

NDA NDA208647

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Rosuvastatin 20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosuvastatin 20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosuvastatin 20. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA208647). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Ezallor Sprinkle

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Function1 trial

Cardiovascular Disease1 trial

Vascular Disease1 trial

Left ventricular diastolic dysfunction1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News